Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval

Regenxbio CEO Curran Simpson at Endpoints' #JPM26 event (Brian Benton Photography) May 14, 2026 07:00 AM EDT Cell/Gene TxFDA+ Re­genxbio's Duchenne study suc­ceed­ed. Will it be enough to con­vince the FDA? Lei Lei Wu News Reporter Re­genxbio said Thurs­day that its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py met the bar in a piv­otal study, and it’s aim­ing for FDA ap­proval in 2027. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER